Literature DB >> 24789502

microRNA-145 inhibits osteosarcoma cell proliferation and invasion by targeting ROCK1.

Pengfei Lei1, Jie Xie1, Long Wang1, Xucheng Yang1, Zixun Dai1, Yihe Hu1.   

Abstract

Osteosarcoma (OS), a malignant mesenchymal sarcoma, is the most frequent primary bone tumor, with a peak incidence in young children and adolescents. The downregulation of microRNA‑145 (miRNA/miR‑145) has previously been identified to be associated with the aggressiveness and metastasis of OS. However, the detailed regulatory mechanism by which miR‑145 inhibits OS remains largely unknown. The present study demonstrated that miR‑145 was significantly downregulated in OS tissues and KHOS and U2OS cell lines. Rho‑associated protein kinase 1 (ROCK1), a key regulator of actin cytoskeleton reorganization, was identified as a novel target of miR‑145. Ectopic expression of miR‑145 notably suppressed the protein expression of ROCK1 without affecting its mRNA level. Furthermore, the expression of ROCK1 was significantly increased in the OS tissues and in the KHOS and U2OS cells. It was further demonstrated that the overexpression of miR‑145 downregulated KHOS and U2OS cell proliferation and invasion, which was reversed by restoration of ROCK1. To the best of our knowledge, the present study demonstrates for the first time that, as a tumor suppressor, miRNA‑145 inhibits OS cell proliferation and invasion, at least in part by directly targeting ROCK1. These results indicate that miR‑145 may be a potential candidate for the diagnosis and treatment of OS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24789502     DOI: 10.3892/mmr.2014.2195

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  13 in total

1.  Analysis of circulating microRNAs during adjuvant chemotherapy in patients with luminal A breast cancer.

Authors:  Ebru Esin Yoruker; Fatma Aydoğan; Uğur Gezer; Pinar Saip; Nejat Dalay
Journal:  Mol Clin Oncol       Date:  2015-05-13

2.  miR-421 is a diagnostic and prognostic marker in patients with osteosarcoma.

Authors:  Shuguang Zhou; Bing Wang; Jun Hu; Yucheng Zhou; Mengzhen Jiang; Mingyu Wu; Liming Qin; Xuming Yang
Journal:  Tumour Biol       Date:  2016-01-13

Review 3.  Review of microRNA in osteosarcoma and chondrosarcoma.

Authors:  Le Chang; Swati Shrestha; Greg LaChaud; Michelle A Scott; Aaron W James
Journal:  Med Oncol       Date:  2015-04-26       Impact factor: 3.064

4.  MicroRNA-145 inhibits growth and migration of breast cancer cells through targeting oncoprotein ROCK1.

Authors:  Meizhu Zheng; Xu Sun; Yongqing Li; Wenshu Zuo
Journal:  Tumour Biol       Date:  2015-12-29

5.  Downregulation of microRNA-497 is associated with upregulation of synuclein γ in patients with osteosarcoma.

Authors:  Liang Wang; Hongwei Gao; Ningji Gong; Mingzhi Gong
Journal:  Exp Ther Med       Date:  2016-10-26       Impact factor: 2.447

6.  Expression and clinical significance of cyclooxygenase-2 and microRNA-143 in osteosarcoma.

Authors:  Yongchao Fang; Zhiqiang Zhang; Qiang Wang; Jianning Zhao
Journal:  Exp Ther Med       Date:  2015-04-14       Impact factor: 2.447

Review 7.  The potential of micelleplexes as a therapeutic strategy for osteosarcoma disease.

Authors:  Catarina Melim; Ivana Jarak; Francisco Veiga; Ana Figueiras
Journal:  3 Biotech       Date:  2020-03-02       Impact factor: 2.406

Review 8.  MicroRNAs and Potential Targets in Osteosarcoma: Review.

Authors:  Valerie B Sampson; Soonmoon Yoo; Asmita Kumar; Nancy S Vetter; E Anders Kolb
Journal:  Front Pediatr       Date:  2015-08-24       Impact factor: 3.418

9.  Phenotypic switching of vascular smooth muscle cells in the 'normal region' of aorta from atherosclerosis patients is regulated by miR-145.

Authors:  Yu-Nan Zhang; Bao-Dong Xie; Lu Sun; Wei Chen; Shu-Lin Jiang; Wei Liu; Fei Bian; Hai Tian; Ren-Ke Li
Journal:  J Cell Mol Med       Date:  2016-03-15       Impact factor: 5.310

10.  MicroRNA-224 promotes the sensitivity of osteosarcoma cells to cisplatin by targeting Rac1.

Authors:  Shuo Geng; Lina Gu; Fang Ju; Hepeng Zhang; Yiwen Wang; Han Tang; ZhengGang Bi; Chenglin Yang
Journal:  J Cell Mol Med       Date:  2016-05-25       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.